[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrence":635},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,36,0,25,[9,40,74,111,141,163,192,216,241,266,287,313,336,365,384,410,420,445,466,490,511,538,560,583,611],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100054214",false,"NCT06476067","Predicting Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Predicting Postoperative Early Tumor Recurrence in Patients With Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Patients who had histologically confirmed ESCC.\n2. Patients who had undergone only complete esophagectomy with radical lymph node dissection without chemotherapy or radiotherapy before or after surgery.\n3. Patients for whom tissue samples are available\n4. Patients who were followed-up completely, with information on observation periods of at least 2 years after surgery.\n5. Written informed consent following full study information is provided to the patient.\n\nExclusion Criteria:\n\n1. Patients lacking clinical information within 2 years of surgery.\n2. Patients with multiple cancers.","ALL","20 Years",{"count":19,"type":20},150,"ESTIMATED","OBSERVATIONAL","The prognosis of patients with esophageal squamous cell carcinoma (ESCC) who develop post-operative early tumor recurrence is often relatively poor. Therefore, biomarker that can detect micro metastases before the start of treatment is required. Epigenomic alterations such as DNA methylation have attracted attention as promising biomarkers. The investigators aim to predict early recurrence based on whole genome DNA methylation analysis of esophageal cancer.",[24,25,26],"Esophageal Cancer","Recurrence","DNA Methylation","RECRUITING","2026-07-10",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":31},"2006-01-01",{"date":35,"type":20},"2028-06-18",{"name":37,"class":38},"City of Hope Medical Center","OTHER",2,{"id":41,"slug":4,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100641148","NCT07656818","Non-Thermal Plasma to Reduce Recurrence in Chronic Subdural Hematoma","Application of Non-Thermal Plasma in the Surgical Bed of Chronic Subdural Hematoma to Reduce the Post-Drainage Recurrence Rate: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults ≥ 18 years of age\n* Diagnosis of symptomatic chronic subdural hematoma (cSDH) requiring surgical drainage (burr hole drainage or craniotomy)\n* Ability to provide written informed consent (or consent from legal representative if patient is incapacitated)\n\nExclusion Criteria:\n\n* Pure acute or subacute subdural hematoma\n* Uncontrolled coagulopathy or bleeding disorder\n* History of intracranial aneurysm or prior cerebrovascular event with residual deficit\n* Presence of active intracranial metallic implants or electronic devices (e.g., programmable shunt, cardiac pacemaker, deep brain stimulator) in the head region\n* Pregnancy or lactation\n* Participation in another interventional clinical trial within 30 days prior to screening","18 Years",{"count":48,"type":20},40,"INTERVENTIONAL",[51],"NA","The goal of this randomized controlled trial is to evaluate whether the adjuvant application of non-thermal plasma (NTP) during standard surgical drainage of chronic subdural hematoma (cSDH) can reduce the recurrence rate at 6 months. The main questions it aims to answer are:\n\n* Does NTP application significantly lower the radiological and clinical recurrence rate of cSDH compared to surgery alone?\n* Is NTP safe when applied to the subdural space and surgical wound bed?\n* Does NTP improve functional outcomes and time to hematoma resolution?\n\nParticipants will be randomly assigned to one of two groups:\n\n* Experimental group (n = 20): Standard burr hole drainage or craniotomy plus intraoperative NTP application over the exposed dura mater, the residual membrane, soft tissue layers, and the skin incision.\n* Control group (n = 20): Standard surgical drainage alone (no NTP).\n\nFollow-up includes clinical assessments and computed tomography (CT) scans at 1 week, 3 months, and 6 months post-surgery. The primary outcome is recurrence (symptomatic reaccumulation requiring re-intervention or ≥50% volume increase on CT).",[54,55,25,56],"Chronic Subdural Hematoma","Subdural Hematoma","Postoperative Complications",[58,59,60,61,62,63],"Non-thermal plasma","Cold plasma","Chronic subdural hematoma","Neurosurgery","Recurrence prevention","Wound healing","2026-06-16",{"date":66,"type":31},"2026-06-18",{"date":68,"type":31},"2026-03-02",{"date":70,"type":20},"2027-04-30",{"name":72,"class":38},"Benjamín Gonzalo Rodríguez Méndez",1,{"id":75,"slug":4,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":49,"phases":85,"briefSummary":87,"conditions":88,"keywords":95,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":39},"100625550","NCT07424092","Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors","Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients","PED-DNX2401","Inclusion Criteria:\n\n* The participant or participant's parents or legally acceptable representatives (if applicable) provides written informed consent for the trial and the pediatric participant provides writ-ten assent, where applicable, based on age and country requirements.\n* Patients with recurrent or refractory high grade malignant brain tumors (high grade glioma, embryonal CNS tumors \\[medulloblastomas, ATRT, EMTR, pineoblastoma\\], and ependymomas) diagnosis based on initial histopathological diagnosis and further clinical and radiological fol-low-up, in whom gross total resection is not feasible, and with a life expectancy of at least 16 weeks at the time of consent.\n* Recurrences within the radiation field will be considered if there is confirmed growth of the lesion in two consecutive MRI or if they occur at least 12 weeks after completion of ra-diation therapy, or if there is clear histopathological confirmation of tumor recurrence.\n* Male and female participants age ≥ 1 years and ≤ 25 years.\n* A single measurable lesion longer than 10 mm in two perpendicular diameters, considered by the investigator to be accessible for safe stereotactic biopsy and virus injection.\n* Lansky Performance Status (LPS) ≥ 60 for participants \\\u003C 16 years, or Karnofsky Performance Status (KPS) ≥ 60 for participants ≥ 16 years.\n* No other chemotherapy or immunotherapy in the 4 weeks before inclusion.\n* Steroids: free off or requiring decreasing or stable corticosteroid dose (≥ 0.05 mg\u002Fkg dexa-methasone daily, or equivalent for other steroids) in the 2 weeks before DNX-2401 admin-istration.\n* Radiation: no craniospinal irradiation, total body irradiation nor focal irradiation in the 6 weeks before inclusion.\n* Autologous Stem Cell Transplantation: patients must be ≥ 3 months post-transplant prior to entry of the study.\n* Patients must be fully recovered from all acute treatment related toxicities of all prior therapies.\n* Laboratory test: adequate hematological (platelets ≥ 100x10e9\u002FL, neutrophils ≥ 1.0x10e9\u002FL, hemoglobin ≥ 5,6 mmol\u002FL), renal function (creatinine \\\u003C1.5 times ULN) and liver function (≤3 times ULN) values.\n* Negative pregnancy test for female participants of child-bearing potential, where child-bearing potential is defined as a fertile female who is pubertal or post-pubertal and not permanently sterile (hysterectomy, bilateral salpingectomy, bilateral oophorectomy).\n* Female participants of child-bearing potential, who are sexually active, agree to use ac-ceptable birth control starting at informed consent and continuing for at least 120 days af-ter DNX-2401 administration. Male participants agree to use acceptable birth control start-ing at informed consent and continuing for at least 90 days after DNX-2401 administration.\n\nExclusion Criteria:\n\n* Any medical or psychological condition or disease that might interfere with the subject's ability to participate or give informed consent (if older than 16 years).\n* Spinal location, or lesions considered risky for stereotactic injection of virus or that might favor entrance of the virus in the ventricular system.\n* Any treatment outside the allowable guidelines outlined in the inclusion criteria.\n* Severe acute infection or intercurrent medical condition including, but not limited to se-vere renal, hepatic, heart or bone marrow failure that based on investigator discretion do not permit inclusion in the study.\n* Subjects with immunodeficiency or autoimmune conditions, active hepatitis or known HIV. No testing for Hepatitis B, Hepatitis C and HIV is required unless mandated by local health authority.\n* Subjects with another primary malignancy.\n* Prior history of encephalitis, multiple sclerosis or other CNS infections or primary CNS dis-ease that would interfere with evaluation.\n* Li Fraumeni Syndrome or a known germ line deficit in the retinoblastoma gene or its relat-ed pathways.\n* Concurrent therapy with any antiviral drug or any immunosuppressive drug (except ster-oids).\n* Life or life-attenuated vaccinations within 30 days prior to DNX-2401 administration and while participating in the study. Killed vaccines are permitted.\n* Prior participant in experimental viral therapy.\n* Inability to undergo MRI scans for any reason.\n* Pregnancy or breastfeeding.","1 Year","25 Years",{"count":84,"type":20},39,[86],"PHASE2","The goal of this clinical trial is to learn if intratumoral administration of DNX-2401 works to treat recurrent and refractory high grade brain tumors in children and young adults. It will also learn about the safety of DNX-2401.\n\nThe main questions it aims to answer are:\n\n* Does a single intratumoral administration of DNX-2401 elicit tumor response and improve survival?\n* Is a single intratumoral administration of DNX-2401 safe and well tolerated?\n\nParticipants will:\n\n* Undergo surgery for tumor biopsy followed by a single intratumoral administration of DNX-2401\n* Visit the clinic periodically for checkups and tests",[89,90,91,25,92,93,94],"High Grade Glioma","Ependymoma","Embryonal Tumor of Brain","Refractory","Pediatric","Young Adult",[96,89,90,97,98,99,100,101],"High Grade Brain Tumors","Embryonal CNS Tumors","Recurrent or refractory","Pediatric and young adult patients","Oncolytic virus","DNX-2401","2026-05-21",{"date":104,"type":31},"2026-05-27",{"date":106,"type":31},"2026-05-12",{"date":108,"type":20},"2029-05",{"name":110,"class":38},"Clinica Universidad de Navarra, Universidad de Navarra",{"id":112,"slug":4,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":49,"phases":119,"briefSummary":120,"conditions":121,"keywords":128,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":39},"100605812","NCT07167381","xDRIVE for Florida-based Cancer Patients","xDRIVE Functional Precision Medicine + Artificial Intelligence Individualized Treatments for Florida-based Cancer Patients With Relapsed\u002F Refractory Cancers","Inclusion Criteria:\n\n* Patients with recurrent\u002Frefractory cancer patients up to age 18 (willing to sign assent if ages 7 - 17 years)\n* -OR- Patients with recurrent\u002Frefractory cancer ≥18 years of age.\n* Patients who have received at least one prior line of standard of care therapy.\n* Patients able to provide treatment and outcome information from previous line(s) of therapy.\n* Patients with sufficient health status to undergo cancer therapy, e.g., Eastern Cooperative Group (ECOG) performance status of 0, 1, or 2 for adult patients.\n* Patients who are scheduled for or have recently undergone a tumor biopsy, excision, or resection.\n* Patients willing to have a blood draw or buccal swab performed for matched normal material for comparison during tumor DNA profiling.\n\nExclusion Criteria:\n\n* Patients who do not have malignant tissue available and accessible, patients where the amount of excised malignant tissue is insufficient material for ex vivo drug testing and\u002For genetic profiling, defined as \\\u003C0.3g for resections or core\u002Ffine-needle biopsies not containing malignant tissue by pathology review, or insufficient malignant tissue in peripheral blood or bone marrow aspirate samples.\n* Patients with insufficient health indicators to undergo therapeutic intervention.",{"count":118,"type":20},210,[51],"Through this study funded by the Florida Cancer Innovation Fund, First Ascent will demonstrate state-wide feasibility of providing xDRIVE Functional Precision Medicine + Artificial Intelligence platform by assessing patient clinical benefit and health economics impacts. As this is a feasibility study, results will be returned to the physician and the physician may use the data to inform the next line of treatment. The investigator will run a prospective single-arm feasibility study providing the xDRIVE FPM AI platform to n = 210+ cancer patients throughout the state of Florida, especially those from underserved populations (pediatric patients and patients in Black, Brown, Hispanic, and rural communities).",[122,123,92,25,124,125,126,127],"Cancer","Neoplams","Leukaemia","Lymphoma","Solid Tumor Malignancies","Solid Cancers",[129,130],"Functional Precision Medicine","Artificial Intelligence","2026-05-17",{"date":133,"type":31},"2026-05-19",{"date":135,"type":31},"2025-11-01",{"date":137,"type":20},"2027-04-01",{"name":139,"class":140},"First Ascent Biomedical Inc.","INDUSTRY",{"id":142,"slug":4,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":49,"phases":149,"briefSummary":150,"conditions":151,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100549505","NCT06434896","Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial","CrEATE","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Informed consent for PLCRC with specific consent for:\n\n  * additional blood withdrawals\n  * collection and use of tissue for scientific research\n  * invitation for future (experimental) research within the cohort, including TwiCs studies\n* Inclusion in observational PLCRC -MEDOCC substudy\n* Histological confirmed stage II colon cancer\n* Fit enough to receive treatment with combination chemotherapy (fluoropyrimidine and oxaliplatin) according to the treating physician\n\nExclusion Criteria:\n\n* Indication for adjuvant chemotherapy according to treating physician\n* Another malignancy in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma\n* Incomplete primary tumor resection (R1 or R2 resection)\n* Contra-indication for fluoropyrimidines or oxaliplatin\n* Pregnancy",{"count":148,"type":20},1320,[51],"Patients in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) with non-metastatic colon cancer that gave consent for additional blood withdrawals are enrolled in the observational PLCRC-MEDOCC substudy. In this study, blood is collected before surgery, after surgery and during follow-up. Within PLCRC-MEDOCC, patients with stage II colon cancer that are not considered to have an indication for adjuvant chemotherapy, can be included in the MEDOCC-CrEATE subcohort under the condition that they gave informed consent in PLCRC for biobanking of tissue and for future studies (Trial within Cohorts design).\n\nPatients included in MEDOCC-CrEATE will be randomized 1:1 to the (A) ctDNA-based treatment group versus (B) the standard of care group. A total of 1320 patients will be randomized. Patients randomized to the ctDNA-based treatment group will have their post-surgery samples analysed directly after informed consent for MEDOCC-CrEATE. All patients with detectable ctDNA will be offered adjuvant chemotherapy (3 months CAPOX). Patients with undetectable ctDNA will receive routine follow-up at the surgical department. The aim of this Trial within Cohorts study is to investigate how many patients with detectable ctDNA after surgery start with adjuvant chemotherapy.",[152,25,153],"Circulating Tumor DNA","Colon Cancer Stage II","2026-05-07",{"date":106,"type":31},{"date":157,"type":31},"2020-03-05",{"date":159,"type":20},"2026-12",{"name":161,"class":38},"UMC Utrecht",29,{"id":164,"slug":4,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":171,"conditions":172,"keywords":176,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":191},"100595302","NCT07030686","Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors","Inclusion Criteria:\n\nTarget trial (ideal RCT)\n\n* Adult (≥18 years of age) patients with history of primary invasive cancer under surveillance at Memorial Sloan Kettering Cancer Center (MSK).\n* Completion of an exercise survey (baseline) as part of MSK Cancer Survivorship Program and completion of a historical survey in the MSK Cancer Survivorship Program 9-15 months (time th) prior reporting non-exercising status \\[i.e., reporting \\\u003C10 metabolic equivalent-hours per week (MET-h\u002Fweek)\\]. Patients completing an additional exercise survey between th and baseline are excluded.\n* No evidence of recurrent or metastatic disease in the 15 months prior to the baseline exercise assessment\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of the historical exercise survey in a MSK Cancer Survivorship Program. Adjuvant hormonal therapy is permitted at any time.\n* Undergoing surveillance in the Cancer Survivorship Program at MSK\n\nEmulation using observational data\n\n* Adult (≥18 years of age) cancer survivors under surveillance at Memorial Sloan Kettering Cancer Center (MSK) between 2011 and 2023.\n* Assessment of self-reported exercise status via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake (baseline assessment).\n* Non-exercising (i.e., reporting \\\u003C5 MET-h\u002Fweek) via completion of an exercise survey as part of MSK Cancer Survivorship Program standard intake 9-15 months prior to the baseline exercise assessment (historical exercise survey).\n* Documented history of the following absolute contraindications to moderate-intensity exercise at any time prior to the baseline exercise assessment, assessed using the Elixhauser ICD codes: Congestive heart failure, valvular disease, chronic pulmonary disease, or renal failure.\n* No evidence of recurrent or metastatic disease via radiological or pathological in EMR in the 15 months prior to the baseline exercise assessment.\n* Completion of all definitive primary adjuvant therapy (e.g., chemotherapy, radiotherapy, targeted therapy) at least 3 months prior to completion of historical exercise survey (i.e., at least 3 months prior to t-1) as part of MSK Cancer Survivorship Program standard intake. Adjuvant endocrine therapy is permitted.",true,{"count":170,"type":20},1000,"This protocol is a retrospective study using observational data to conduct a target trial emulation to examine the association of exercise on cancer specific endpoints and other clinical outcomes in cancer survivors.",[173,174,25,122,175],"Survivorship","Recurrent","Remission",[173,177,178,179,180,181,182],"Exercise","cancer survivor","adult cancer survivor","no evidence of disease","20-101","Memorial Sloan Kettering Cancer Center","2026-04-27",{"date":185,"type":31},"2026-04-28",{"date":187,"type":31},"2020-03-19",{"date":189,"type":20},"2027-03-19",{"name":182,"class":38},4,{"id":193,"slug":4,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":16,"minAge":198,"maxAge":4,"enrollmentInfo":199,"targetDuration":4,"studyType":49,"phases":201,"briefSummary":202,"conditions":203,"keywords":204,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":73},"100546961","NCT06401772","The Effectiveness and Safety of Body Posture in Preventing Postoperative Recurrence for Chronic Subdural Hematoma","The Effectiveness and Safety of Body Posture to Improve Intracranial Pressure in Preventing Postoperative Recurrence for Chronic Subdural Hematoma (BP-CSDH) -A Multicenter Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n1. chronic subdural hematoma is diagnosed with CT\u002FMRI scan; thickness of hematoma is more than 1 cm;\n2. more than 60 years of age or 60 years;\n3. MGS-GCS (Markwalder's Grading Scale and Glasgow Coma Scale) is less than or equal to 2;\n4. patients have neurological symptom caused by CSDH before surgery, such as headache, dizziness, nausea, vomiting, numbness or weakness of limb, instability to walk, unconsciousness, trouble speaking, insensitive, etc.\n5. receive burr hole drainage;\n6. sign informed consent voluntarily.\n\nExclusion Criteria:\n\n1. have brain hernia or acute massive cerebral infarction that have to perform craniotomy\n2. have severe malignancies, hemorrhagic disease, cardiac dysfunction and other serious disease that may impede recovery or follow-up compliance;\n3. Spinal deformities (e.g., kyphosis) or psychiatric disorders precluding prolonged body posture therapy adherence\n4. Concomitant severe intracranial tumors, aneurysms, or vascular malformations that may impede recovery.\n5. Patients with cranial CT demonstrating no significant compression or displacement of brain tissue, asymptomatic presentation, and unaffected daily activities were deemed ineligible for surgical intervention by neurosurgeons;\n6. CSDH persisting for over 1 year and exhibiting marked organization\u002Fsolidification of the hematoma;\n7. CSDH caused by over V-P shunting;\n8. during burr hole drainage, patients have to perform craniotomy due to acute bleeding or brain hernia;\n9. Intraoperative complications (e.g., cerebral contusion, intraparenchymal catheter placement) during burr hole drainage;\n10. have deep venous thrombosis of lower extremity or pulmonary embolism;\n11. cannot complete regular reexamine within 1 year for any reason;\n12. life expectancy less than 1 year;\n13. participating other ongoing clinical trial;\n14. patients are not qualified for other reason evaluated by two neurosurgeons;\n15. have bile reflux gastritis and esophageal diseases.","60 Years",{"count":200,"type":20},830,[51],"This study aims to investigate the effectiveness and safety of body posture to improve intracranial pressure in preventing postoperative recurrence for chronic subdural hematoma",[54,25],[54,205,206],"body posture","intracranial pressure","2026-04-26",{"date":209,"type":31},"2026-04-30",{"date":211,"type":31},"2024-08-08",{"date":213,"type":20},"2028-01",{"name":215,"class":38},"Huashan Hospital",{"id":217,"slug":4,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":221,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":223,"targetDuration":4,"studyType":49,"phases":225,"briefSummary":226,"conditions":227,"keywords":229,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":4},"100632104","NCT07509346","Fecal Microbiota Transplant vs Standard Treatment for Recurrent Non-Obstructive Cholangitis","Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Fecal Microbiota Transplantation Versus Standard Treatment in Patients With Recurrent Non-Obstructive Acute Cholangitis - COLANBIOTA Trial","COLANBIOTA","Inclusion criteria - Patients ≥18 years of age who have had ≥2 episodes of acute cholangitis in the past year.\n\nExclusion criteria\n\n* Oral intolerance or inability to swallow capsules.\n* Pregnancy or breastfeeding.\n* Any clinically significant disease (other than RAC) such as disseminated malignancy or organ failure resulting in relevant cardiac, hepatic, pulmonary, or neurodegenerative disease with an expected survival of less than one year.\n\nInability to understand the study, sign the informed consent, and\u002For collect stool samples.\n\n\\- RAC due to the presence of choledocholithiasis (any number of stones in the biliary tract) or extrahepatic bile duct stricture that cannot be resolved by surgical or endoscopic treatment. Lack of resolution of extrahepatic biliary obstruction is defined as failure to remove all stones, or a residual diameter in stricture cases of less than 75% of the bile duct diameter above and below the stricture, even after balloon dilation and\u002For biliary stent placement",{"count":224,"type":20},44,[86],"Patients with abnormalities of the biliary tract (the system that connects the liver to the small intestine and allows bile to flow) are prone to the development of strictures, dilations, or other problems that impede bile flow and promote the formation of gallstones. All of this leads to the development of infections in this anatomical region known as cholangitis. These infections typically require the patient to be admitted to the hospital, either to a general ward or even the ICU. These are, therefore, serious infections that threaten the patient's survival. Unfortunately, one-quarter of these patients experience not just one, but multiple infections of this type over an extended period of time. This condition is called acute recurrent cholangitis (ARC).\n\nIt is important to note that the antibiotics used to treat these repeated infections lead to the selection of more resistant and virulent bacteria that remain in the intestine for months or years and, in turn, promote the recurrence of these infectious episodes. ARC affects a more vulnerable population, which, combined with the proliferation of resistant bacteria, increases the risk of serious complications and a reduced response to available treatments.\n\nReplacing these dangerous gut bacteria with bacteria from healthy donors is a strategy that has proven effective in reducing recurrent urinary tract infections. A similar approach has been successful in patients with chronic vaginal infection (vaginosis). This gut microbiota replacement is currently being investigated for a wide range of diseases affecting various sites, with promising results in some cases. There is strong evidence that this strategy may also be effective in patients with recurrent episodes of cholangitis.\n\nThe procedure is considered very safe and is subject to strict safety measures to prevent risks to the recipient of these bacteria (requirements similar to those used for blood transfusions). If this strategy proves effective, it could reduce patient suffering and even mortality, as well as save money spent on hospital stays and medications, and contribute to reducing antibiotic use and the emergence of bacterial resistance. Even if no significant clinical benefit is demonstrated in this clinical setting, the information obtained will contribute to increasing knowledge about the role of the fecal microbiota, the technical and scientific aspects of fecal microbiota transplantation, and its potential uses. It should be noted that a patient association called ALBI España (Association for the Fight Against Inflammatory Biliary Diseases) has participated in the study's design and strongly supports this research, which could lead to a reduction in mortality among its patients and a reduction in adverse effects and costs associated with hospital admissions and antibiotic use.\n\nIn summary, the use of FMT in patients with AC could have a significant impact on treatment effectiveness, reducing new episodes of cholangitis. This would improve patients' quality of life-including their physical, emotional, and social well-being-by reducing hospitalizations and associated complications. Another clear benefit would be the reduction in the proliferation of resistant bacteria and a lower use of antibiotics. The use of TMF would increase the autonomy of the National Health System (SNS) by enabling it to develop and manage non-commercial, non-profit therapies with low production costs, which would guarantee equitable access for patients to an effective and safe therapy.",[228,25],"Cholangitis Acute",[230],"FMT for recurrent acute cholangitis","NOT_YET_RECRUITING","2026-04-07",{"date":234,"type":31},"2026-04-13",{"date":236,"type":20},"2026-06-01",{"date":238,"type":20},"2029-12-31",{"name":240,"class":38},"Puerta de Hierro University Hospital",{"id":242,"slug":4,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":246,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":49,"phases":250,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":4},"100629748","NCT07478705","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer Using Liquid Biopsy and Imaging","Early Detection of Metastatic Recurrence Among Patients With Stage II or III Triple Negative Breast Cancer (TNBC) Using Liquid Biopsy and Imaging: A Multi-Center Pilot Randomized Trial (EINSTEIN-TNBC)","EINSTEIN-TNBC","Inclusion Criteria:\n\n* Men or women aged 18 and over\n* Biopsy proven invasive triple negative breast cancer (defined here as estrogen receptor \\\u003C10%, progesterone receptor \\\u003C10%, human epidermal growth factor receptor 2 (HER2) negative status, with HER2 status being defined as per ASCO\u002FCAP guidelines)\n* T2-4\u002FN0 (\\>2 cm primary breast cancer as assessed clinically or on imaging in the absence of nodal involvement) OR T1c-4\u002FN1-3 disease (\\>10mm with fine needle aspirate or core biopsy confirming nodal involvement is required)\n* Residual disease (RCB 2 or 3) on surgical specimen after completion of neoadjuvant chemo(-immuno)therapy\n\nExclusion Criteria:\n\n* Inability to provide informed consent. Participants who require translators are allowed to enroll\n* Prior history of invasive breast cancer -Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the detection of BC recurrence on a liquid biopsy (patients with a history of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and carcinoma-in-situ of cervix are permitted to participate)-\n* Pregnant patients are not permitted\n* Creatinine clearance \\\u003C45 mL\u002Fmin using the Cockcroft-Gault equation.",{"count":249,"type":20},30,[51],"Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer, often with poor outcomes. Currently, follow-up for TNBC consists of physical exams and annual breast imaging, with additional scans only if symptoms appear. This approach may delay the detection of the cancer coming back until the disease is advanced.\n\nA promising new technique is the detection of circulating tumor DNA (ctDNA)-in the blood. Studies suggest ctDNA may identify cancer recurrence months before it becomes visible on scans or causes symptoms. However, it is unknown whether detecting recurrence earlier can actually help patients live longer or feel better.\n\nThe EINSTEIN-TNBC trial is a study aiming to evaluate the feasibility of ctDNA-guided surveillance for patients with TNBC after surgery.\n\nThirty participants will be randomized to either:\n\nStandard of care (routine physical exams and annual breast imaging), or Active surveillance (standard of care plus ctDNA testing, with imaging investigations if ctDNA is detected).\n\nThis study will assess the feasibility of conducting a ctDNA-based monitoring trial in this patient population.\n\nIf feasible, EINSTEIN-TNBC will lay the foundation for a larger future clinical trial to determine whether earlier detection of metastatic TNBC can improve survival and quality of life.",[253,254,25,255],"Triple Negative Breast Cancer","Surveillance","ctDNA",[255,253,254,25],"2026-03-13",{"date":259,"type":31},"2026-03-17",{"date":261,"type":20},"2026-05-01",{"date":263,"type":20},"2029-05-01",{"name":265,"class":38},"Sunnybrook Health Sciences Centre",{"id":267,"slug":4,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":275,"conditions":276,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":39},"100545240","NCT06379321","Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System","A Retrospective\u002FProspective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon Hinge Knee (THK) System","Hinge","Inclusion Criteria:\n\n* The subject undergoes a primary or revision procedure implanting at least the Revision Baseplate portion of the Triathlon Hinge Knee System in accordance with the Indications for Use.\n* The subject has signed an Institutional Review Board (IRB)\u002FEthical Committee (EC)-approved, study-specific Informed Consent Form (ICF).\n* The subject is a male or non-pregnant female at the time of enrollment.\n* The subject agrees to comply with the protocol-mandated clinical evaluations.\n\nExclusion Criteria:\n\n* Any active or suspected latent infection in or about the knee joint; overt infection;\n* Distant foci of infection which may cause hematogenous spread to the implant site; rapid disease progression as manifested by joint destruction or bone resorption apparent on roentgenogram;\n* skeletally immature patients;\n* Severe instability of the knee joint secondary to the absence of collateral ligament integrity and function.\n* Bone stock compromised by disease, infection or prior implantation which cannot provide adequate support and\u002For fixation to the prosthesis.\n* Known or suspected sensitivity and\u002For allergy to any material in the device.\n* Conditions presenting an increased risk of failure include:\n* uncooperative patient or patient with neurologic disorder, incapable of following instructions;\n* osteoporosis;\n* metabolic disorders which may impair bone formation or cause bone loss;\n* osteomalacia; and,\n* previous arthrodesis.\n* A higher incidence of implant failure has also occurred in paraplegics, cerebral palsy and patients with Parkinson's disease.\n* Any mental or neuromuscular disorder which would create an unacceptable risk of prosthesis instability, prosthesis fixation failure, or complications in postoperative care.\n* The subject is a prisoner",{"count":274,"type":20},200,"This study is a prospectively and retrospectively enrolled, post-market, open-label, non-randomized, single institution evaluation of clinical outcomes of primary or revision knee surgery patients who meet the eligibility criteria and received devices from the Triathlon Hinge Knee System according to its indications for use (IFU).\n\nClinical evaluation for all cases will include data collection of patient demographics, surgical details, early postoperative status, functional and clinical outcomes, and survivorship at 1, 2, 6, and 10-years.",[277,25,278],"Knee Arthropathy","Knee Infection","2026-02-27",{"date":68,"type":31},{"date":282,"type":31},"2024-05-10",{"date":284,"type":20},"2034-05-10",{"name":286,"class":38},"The Cleveland Clinic",{"id":288,"slug":4,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":293,"targetDuration":295,"studyType":21,"phases":4,"briefSummary":296,"conditions":297,"keywords":300,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":39},"100482088","NCT05557474","Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit","Development and Clinical Validation of Early-stage Lung Cancer Prognostic Kit and Immunotherapy Companion Diagnostic Laboratory Developed Tests","Inclusion Criteria:\n\n* Willing to sign and provide subject consent.\n* Male or female of age 20 or older.\n* Patients diagnosed with lung adenocarcinoma by tumor pathology.\n* Lung cancer with the pathological stage of IA\u002FIB\u002FII\u002FIIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition).\n* Complete tumor resection (R0 resection).\n* The East Coast Cancer Clinical Research Collaborative (ECOG) performance status was 0 or 1 at the time of grouping.\n* Those willing to provide tumor tissue or cytology specimens (including surgical specimens, tissue biopsy specimens, or cytology specimens), blood and body fluid specimens (for follow-up or disease recurrence, such as urine, malignant pleural effusion, ascites, pericardial fluid, etc.).\n\nExclusion Criteria:\n\n* Not primary lung cancer patients.\n* Lung cancer patients whose pathological stage is not IA\u002FIB\u002FII\u002FIIIA according to the American Joint Committee on Cancer Staging Manual (8th Edition) after surgery.\n* Patients with uncontrolled malignant tumors other than lung cancer.\n* Uncontrolled systemic disease (such as diabetes, hypertension, active infection, etc.) (determined by the principal investigator )\n* Pregnant women.\n* Any condition may put the patient at serious risk, may affect the interpretation of the trial results, or may seriously interfere with the patient's participation in the trial.",{"count":294,"type":20},236,"5 Years","Lung cancer is the leading cause of cancer mortality worldwide in spite of the advanced progresses in medication and low-dose CT screening. The early-stage lung cancer accounts for less than 50% of newly diagnosed lung cancer in Taiwan, even in stage IB patients proximately 30% still suffer from recurrence and metastasis.\n\nThe International Cancer Moonshot Project recently established the first comprehensive proteogenomics profiling of early-stage lung cancer patients in East Asia, revealing a proteomics-informed classification to identify a new \"late like\" subtype, which can identify a subgroup of early-stage patients with worse clinicopathological features (Cell, Cover story, 2020). This study has been featured in prestigious journals (Nat Rev Clin Oncol; Cancer Discov, 2020) and led to two provisional US patents. In this proposal, taking the discovery from the Cancer Moonshot multiomics database, the investigators aim to translate these findings into clinical utilities. Two subprojects are proposed. (1) Validation of \"late-like\" protein markers for identifying high-risk early-stage lung cancer: Two IVD kits will be developed, including high-risk early-stage lung cancer IHC prediction kit for tumor staining and high-risk early lung cancer ELISA prediction kit for noninvasive diagnosis. (2) Conducting a prospective clinical trial to evaluate the accuracy of high-risk early-stage lung cancer IHC prediction kit and high-risk early-stage lung cancer ELISA prediction kit.",[298,299,25],"Lung Cancer","Surgery",[298,301,302,303,25],"Immunohistochemistry","Enzyme-linked Immunosorbent Assay","Laboratory developed tests","2026-02-12",{"date":306,"type":31},"2026-02-17",{"date":308,"type":31},"2021-10-01",{"date":310,"type":20},"2028-12-31",{"name":312,"class":38},"Chung Shan Medical University",{"id":314,"slug":4,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100622120","NCT07379489","Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma","Efficacy of Postoperative Adjuvant PD-1 Inhibitors Guided by a Deep Learning Model: a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Aged between 18 and 75;\n* achieved complete tumor resection;\n* histological verification of HCC;\n* liver function classified as Child-Pugh grade A or B;\n* No other serious systemic disease or organ dysfunction.\n\nExclusion Criteria:\n\n* history of other malignancies or recurrent HCC;\n* extrahepatic metastasis;\n* prior treatments for HCC;\n* ongoing severe postoperative complications;\n* mixed or other types of liver cancer;\n* received other adjuvant therapy.","75 Years",{"count":321,"type":20},300,"Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.",[324,325,25,326],"HCC","Adjuvant Therapy","Immune Checkpoint Inhibitor","2026-01-23",{"date":329,"type":31},"2026-01-30",{"date":331,"type":20},"2026-01-31",{"date":333,"type":20},"2031-12-31",{"name":335,"class":38},"Tongji Hospital",{"id":337,"slug":4,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":49,"phases":346,"briefSummary":347,"conditions":348,"keywords":351,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":73},"100619696","NCT07347977","Lidocaine Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk","Lidocaine Infusion Decreases Postoperative Lung Cancer Reoccurance and Metatasis Risk: a Multicenter Randomized Controlled Study","LidCRM","Inclusion Criteria:\n\n1. Age range: 18-80 years old.\n2. Electively undergo minimally invasive (thoracoscopic or robotic) surgery for the treatment of lung cancer\n3. Is willing and capable of providing consent.\n\nExclusion Criteria:\n\n1. Palliative surgery without intention of cure.\n2. Extensive comorbidities (ASA IV).\n3. Patients with known or suspected allergy to lidocaine.\n4. Patients who are currently pregnant or breastfeeding.\n5. Patients who may experience adverse reactions due to accumulation of lidocaine during intravenous infusion, as stated in the Summary of Product Characteristics (SmPC) for lidocaine.\n6. Currently, there is abnormal liver function, with ALT or AST levels exceeding the laboratory reference range by a factor of 2.\n7. Currently, there is severe renal insufficiency (serum creatinine ≥451umol\u002FL or glomerular filtration rate (calculated using the MDRD formula) \\\u003C30ml\u002Fmin).\n8. Epilepsy.\n9. Patients with cardiac conduction abnormalities, including second-degree or third-degree heart block without a pacemaker, left bundle branch block, sick sinus syndrome, and pre-excitation syndrome (confirmed by medical history and electrocardiogram), as well as those with low cardiac output due to reduced left ventricular ejection fraction.\n10. Concurrent use with continuous infusion of other local anesthetic drugs (such as epidural).\n11. Patients who use drugs that may cause reasons for exclusion, including Class I and Class III antiarrhythmic drugs (such as mexiletine and amiodarone), cimetidine, and antiviral drugs. Eligibility will be determined by local clinicians and verified by clinical trial doctors.\n12. Patients with body weight \\\u003C40kg","80 Years",{"count":345,"type":20},1400,[51],"The goal of this clinical trial is to explore if perioperative lidocaine infusion decreases disease reoccurrence and metastasis risk in non-small cell lung cancer patients.\n\nParticipants will be randomly assigned (1:1) to the lidocaine or placebo group. The intervention initiates within 30 minutes before anesthesia induction with an intravenous loading dose of 1.5 mg\u002Fkg administered over 10-20 minutes. This is followed by a continuous maintenance infusion of 1.5-3 mg\u002Fkg\u002Fh (calculated as 1-1.5 mg\u002Fkg\u002Fh in protocol text, see note below) during surgery, terminating 1 hour after skin closure. Participants will be followed up for 36 months post-surgery. Blood samples will be collected at baseline, postoperative day 1, day 3, and upon discharge",[349,25,350],"Non-Small Cell Lung Cancer","Survival Analysis",[352,353,25,354],"Lidocaine","Non-small cell lung cancer","Survival analysis","2026-01-11",{"date":357,"type":31},"2026-01-16",{"date":359,"type":20},"2026-01-01",{"date":361,"type":20},"2029-12-30",{"name":363,"class":364},"First Affiliated Hospital of Ningbo University","NETWORK",{"id":366,"slug":4,"hasResults":11,"nctId":367,"briefTitle":368,"officialTitle":369,"acronym":4,"eligibilityCriteria":370,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":319,"enrollmentInfo":371,"targetDuration":4,"studyType":49,"phases":373,"briefSummary":374,"conditions":375,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":383,"locationsCount":73},"100619915","NCT07350824","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC","Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in Hepatocellular Carcinoma: A Prospective, Multicenter Study","Inclusion Criteria:\n\n* Age between 18 and 75 years, inclusive, regardless of gender.\n* Newly diagnosed, treatment-naïve patients with HCC.\n* Received radical treatments, such as liver resection or microwave ablation.\n* Combine at least one of the risk factors for tumor recurrence, such as microvascular\u002Fmacrovascular invasion, poor differentiation, satellite nodules, multiple tumors, and tumor diameter greater than 5 cm.\n* Child-Pugh liver function score ≤ 7.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Absence of severe organic diseases affecting the heart, lungs, brain, or other major organs.\n\nExclusion Criteria:\n\n* History of other malignancies.\n* Recurrent HCC.\n* Prior systemic therapy for HCC.\n* Unable to complete the follow-up and dynamic MRD monitoring.\n* Having an immune deficiency disorder.\n* Allergic to PD-1 inhibitors or unable to tolerate related treatments.",{"count":372,"type":20},276,[51],"Hepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge. Adjuvant immune checkpoint inhibitors (ICIs) show promise in improving outcomes, but biomarkers to identify patients who will benefit are lacking. Current clinicopathological risk factors for minimal residual disease (MRD) are suboptimal in sensitivity and specificity.\n\nCirculating tumor DNA (ctDNA) analysis, reflecting real-time tumor dynamics, offers a promising approach for MRD detection. This study focuses on the methylation status of GNB4 and Riplet-genes located within HCC-associated CpG islands-using a bespoke bisulfite-conversion and qPCR assay to sensitively detect methylated alleles, thereby enabling MRD monitoring.\n\nTo clinically validate this approach, we will conduct a prospective, multicenter cohort study assessing the predictive value of serial \\*GNB4\u002FRiplet\\* methylation testing for recurrence and adjuvant therapy benefit.",[324,376,25],"Minimal Residual Disease","2026-01-09",{"date":379,"type":31},"2026-01-20",{"date":381,"type":20},"2025-12-31",{"date":310,"type":20},{"name":335,"class":38},{"id":385,"slug":4,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":49,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":191},"100563841","NCT06621407","A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma","Active 24 Hours Subperiostal vs. 24 Hours Passive Subdural Drainage Following Burr Hole Evacuation of Chronic Subdural Hematoma (the SUPERDURA Trial) - Protocol for a Nationwide Randomized Clinical Non-inferiority Trial","SUPERDURA","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Patients with symptomatic CSDH confirmed on brain CT- or magnetic resonance imaging (MRI), admitted to a Danish neurosurgical department for surgical treatment.\n* Patients undergoing a single burr-hole evacuation.\n* Informed written and oral consent is taken prior to surgery.\n\nExclusion Criteria:\n\n* Patients who are mentally incapacitated\n* Patients with known abnormalities in their cerebrospinal fluid (protein and glucose levels, cell count, and type)\n* Patients with changes or abnormalities in their normal cerebrospinal fluid dynamics, e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, and ventricular peritoneal shunt.\n* Patients with additional\u002Fpreviously intracranial pathology that requires\u002Fhas required neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess).\n* Patients with recurrent CSDH or with previous craniotomy or other transcranial surgery (for any reason)\n* Patients unable to give consent prior to surgery",{"count":392,"type":20},354,[51],"Chronic subdural hematoma (CSDH) is a common disease. The main treatment is neurosurgical evacuation and subsequent hematoma drainage. However, consensus on the optimal drain placement site, and whether the drainage should be active or passive, is lacking.\n\nThe aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH.\n\nThe study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark.\n\nAdult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides.\n\nBefore surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage.\n\nThe patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence.\n\nSecondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures.\n\nSample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years.\n\nEthics approval for inclusion of competent patients has been obtained (N-20240009).",[54,396,25,397,398,399,400],"Surgical Procedures, Operative","Mortality","Drainage","Drainage\u002FMethods","Drainage Procedure","2025-11-20",{"date":403,"type":31},"2025-11-25",{"date":405,"type":31},"2025-09-01",{"date":407,"type":20},"2027-11",{"name":409,"class":38},"Aalborg University Hospital",{"id":411,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":413,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":419,"locationsCount":39},"100552667",{"count":19,"type":20},[24,25,26],"2025-07-09",{"date":416,"type":31},"2025-07-11",{"date":33,"type":31},{"date":66,"type":20},{"name":37,"class":38},{"id":421,"slug":4,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":49,"phases":429,"briefSummary":430,"conditions":431,"keywords":434,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":73},"100501112","NCT05805020","Cellvizio to Evaluate Margins in Crohn's Ileal Disease","Is There a Concordance Between the Cellvizio With an Intravenous Injection of Fluorescein and the Pathology to Determine the Microscopic Inflammation at the Ileal Resection Margins in Crohn's Ileal Disease","CELLVICROHN","Inclusion Criteria:\n\n* Patients who need a ileocaecal resection for a Crohn disease whatever is the phenotype of the Crohn's disease\n\nExclusion Criteria:\n\n* Patients\\\u003C18 years old,\n* pregnancy or breastfeeding,\n* patients who have an ileocolic resection for a surgical recurrence of the Crohn's disease.\n* Patients operated in emergency for a peritonitis,\n* patients who have a contra-indication for fluorescein injection or severe allergia to any drug",{"count":428,"type":20},41,[51],"Crohn disease is an inflammatory bowel disease. A surgical procedure is required in about 80% of cases. Surgery doesn't cure from Crohn's disease but the type of surgery remains important as there are several intraoperative risk factors for recurrence. Among these factors the microscopic inflammation at the resection margins. This is a crucial point, if the resection is too large there is a risk of short bowel syndrome, if the resection is too short (microscopic inflammation at resection site), there is a higher risk of postoperative recurrence (75% vs 46% at 18 months). Surgeons have to do a limited resection (2cm from macroscopic crohn disease). However this macroscopic non inflammatory resection margin can be microscopically inflammatory (up to 80%). Thus it is useful to evaluate if there is a microscopic inflammation at the resection margin. Moreover there is an increase interest for the role of the mesentery for recurrence but its role remains unclear. It is of interest to clarify the border between the inflammatory and non-inflammatory mesentery. Cellvizio is a confocal laser endomicroscopy providing the possibility of obtaining in vivo high-magnification images of the gut epithelium. This allows real-time examination of the gastrointestinal mucosa at the cellular and subcellular level. Cellvizio has never been used during surgery for Crohn disease.\n\nThe aim of this study is to evaluate the intraoperative use of Cellvizio (using the CelioFlex microsonde) with an intravenous injection of fluorescein to determine the best ileal resection margins in Crohn disease.",[432,433,25],"Crohn Disease","Resection Margins",[432,433,435],"recurrence","2025-05-22",{"date":438,"type":31},"2025-05-28",{"date":440,"type":31},"2022-03-03",{"date":442,"type":20},"2026-03",{"name":444,"class":38},"Centre Hospitalier Universitaire, Amiens",{"id":446,"slug":4,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":451,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":73},"100592444","NCT06993506","Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","Sacituzumab Tirumotecan Monotherapy or Combination Therapy in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Negative Breast Cancer: A Real-World Study","Inclusion Criteria:\n\n1. Aged ≥ 18 years old at the time of signing the informed consent form, regardless of gender;\n2. Patient must meet one of the following pathological diagnoses and classifications:\n\n   2.1) For TNBC Cohort: -Histological\u002Fcytological confirmed of triple-negative breast cancer (TNBC) from the most recent pre-SKB264 biopsy\u002Fpathological report, with: HER2 negative: immunohistochemistry (IHC) of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH); Estrogen and progesterone receptor negative means that less than 1% of the cells express hormone receptors as indicated by IHC; -Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection); 2.2) For HR+\u002FHER2- BC Cohort: -Histological\u002Fcytological confirmed of HR+\u002FHER2- breast cancer from the most recent pre-SKB264 biopsy\u002Fpathological report, with: HER2 negative: IHC of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by FISH; HR positive: Hormone receptor-positive (HR, ER, or PR status) was defined as ≥1% expression by IHC.-Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection);\n3. Plan to receive SKB264 monotherapy or combination therapy;\n4. Prior treatment lines: -For TNBC Cohort: ≤2 lines of systemic antitumor therapy for unresectable locally advanced, recurrent, or metastatic disease; -For HR+\u002FHER2- BC Cohort: ≤2 lines of systemic antitumor therapy (excluding endocrine therapy) for unresectable locally advanced, recurrent, or metastatic disease;\n5. Voluntarily participate in the study, sign the informed consent form and demonstrate good compliance.\n\nExclusion Criteria:\n\n1. Patients with other malignancies, except cured basal or squamous cell skin cancer or in situ cancer of cervix; and patients with other malignancies must have a tumor-free period of at least 5 years;\n2. Patients who are currently participating in other interventional clinical studies;\n3. Known allergy to the investigational drug or any of its components;\n4. Pregnant or lactating women;\n5. Any situation that the researchers consider to interfere with the evaluation of the study drug or the safety of the subjects or the analysis of the study results, or any other situation that the researchers consider inappropriate to participate in this study.",{"count":452,"type":20},500,"This study is a multi-center observational real-world study, with a total of 500 patients planned to be enrolled. This study is divided into two cohorts: the triple-negative breast cancer (TNBC) cohort and the hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer (HR+\u002F HER2-BC) cohort. The aim of this study is to assess the efficacy and safety of Sacituzumab Tirumotecan (SKB264) monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer in the real-world setting.",[455,25,456],"HER2-negative Breast Cancer","Metastasis","2025-05-20",{"date":459,"type":31},"2025-05-29",{"date":461,"type":20},"2025-08-01",{"date":463,"type":20},"2027-10-31",{"name":465,"class":38},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":467,"slug":4,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":49,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":489},"100586158","NCT06911736","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence","Effect of the Postoperative Trendelenburg Position on Chronic Subdural Hematoma Recurrence: a Clinical Trial","POTHeR","Inclusion Criteria:\n\n* The study included patients aged 18 years or older who required surgical management of symptomatic CSH confirmed by CT scan and whose informed consent was given by the patient or responsible family member to participate in the study\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Conditions in which the trendelenburg position might not be safe, such as intracranial hypertension without a drain to allow evacuation of the hematoma, cardiovascular instability (severe heart failure, unstable angina, cardiogenic pulmonary edema), acute respiratory distress syndrome without a secure airway, glaucoma, spinal cord trauma not stabilized with surgery, peripheral vascular disease,\n* History of ipsilateral chronic subdural hematoma drainage, intracranial hypotension syndrome, ventriculoperitoneal shunting\n* Simultaneous participation in any other clinical trial.",{"count":474,"type":20},254,[51],"Objective: Determine the effect of the postoperative trendelenburg position on the recurrence of chronic subdural hematoma (CSH) in patients undergoing surgery.\n\nMaterials and Methods: An open-label, randomized, controlled clinical trial was conducted in three hospitals in Medellín. Patients with CSH were enrolled and assigned to the trendelenburg position (30° leg elevation and 10° head tilt) or a flat bed for 24 hours postoperatively. CSH recurrence was measured at 3 months, along with functional outcome (modified Rankin scale), adverse events, and comfort (Likert scale).",[54,478,25,397,479,480],"Trendelenburg","Prognosis","Clinical Trials","2025-04-16",{"date":483,"type":31},"2025-04-22",{"date":485,"type":31},"2024-06-01",{"date":70,"type":20},{"name":488,"class":38},"Universidad de Antioquia",3,{"id":491,"slug":4,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":4,"eligibilityCriteria":495,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":343,"enrollmentInfo":496,"targetDuration":4,"studyType":49,"phases":498,"briefSummary":499,"conditions":500,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":502,"lastUpdatePostDateStruct":503,"startDateStruct":505,"completionDateStruct":507,"leadSponsor":509,"locationsCount":73},"100269049","NCT02781870","Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible Mesh With or Without LiquiBand Fix 8 Mesh Fixation","Randomized Single-center Study on Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible With and Without LiquiBand Fix 8 Mesh Fixation","Inclusion Criteria:\n\n* adult patients presenting with primary unilateral inguinal hernia\n* patients planed for a laparoscopic repair\n\nExclusion Criteria:\n\n* Age below 18 years\n* recurrent or incarcerated hernias\n* open hernia repair and bilateral hernias\n* concomitant repair of another kind of abdominal hernia\n* combined surgical procedures\n* no informed consent\n* pregnant women\n* ASA score 4 or more\n* contra-indications for MRI scans.",{"count":497,"type":20},100,[51],"This study aims to visualize the implanted mesh in vivo by MRI in 20 patients at 1 month and 12 months post-operatively. Moreover, we want to evaluate the safety and efficiency of non-penetration mesh fixation techniques using pre-designed ENDOLAP 3D visible mesh placement versus mesh fixation using a synthetic LiquiBand Fix 8 glue for laparoscopic treatment of groin hernias.\n\nA total of 100 male and female patients will be entered in the trial in Maria Middelares Ghent, for which an inclusion period of 24 months is anticipated. Four surgeons of the department of surgery will screen all eligible consecutive patients for inclusion in the study. They will inform all patients about the surgery and the follow-up with MRI scan thereafter.",[501,25],"Hernia","2025-04-10",{"date":504,"type":31},"2025-04-11",{"date":506,"type":31},"2016-05-09",{"date":508,"type":20},"2027-08",{"name":510,"class":38},"Algemeen Ziekenhuis Maria Middelares",{"id":512,"slug":4,"hasResults":11,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":4,"eligibilityCriteria":516,"healthyVolunteers":168,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":517,"targetDuration":4,"studyType":49,"phases":519,"briefSummary":520,"conditions":521,"keywords":525,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":536,"locationsCount":73},"100532283","NCT06210789","Periodontal Plastic Reconstruction of Soft Tissue Dehiscences After the Removal of Localized Gingival Enlargements","Periodontal Plastic Surgical Approaches to Correct Recession and Lack of Keratinized Tissue After Elimination of Localized Gingival Enlargements - a Case Series","Inclusion Criteria:\n\n* patients older than 18 years\n* systematically healthy patients\n* localized gingival enlargement is present that involves maximum 3 teeth\n\nExclusion Criteria:\n\n* pregnant women\n* medication intake that can potentially affect the oral mucosa and its healing\n* heavy smokers (\\>=15)",{"count":518,"type":20},22,[51],"Non-inflammatory recessions and Miller class I-II-III. mucogingival defects after elimination of localized gingival enlargements are frequently encountered challenges in the daily practice. In Miller class II-III. recessions the lack of keratinized tissues often compromise the maintenance a proper oral hygiene, this can cause inflammation, which can result in further periodontal attachment loss. In the literature there are some approaches that aim at widening of keratinized tissues and root coverage at the same time, such as the subperiosteal envelope technique (SET) (Allen 1994) combined with a subepithelial connective tissue graft (SCTG) or a partially epithelialized connective tissue graft (PE-SCTG) (Stimmelmayr 2011). In the eradication of localized gingival enlargement postoperative complications following surgical removal, such as recurrence and subsequent gingival recessions as well as loss of keratinized tissues are commonly observed. Nevertheless, a state of the art comprehensive treatment approach has not been reported yet to overcome the above mentioned sequels. The aim of this study is to present a periodontal plastic surgical approach to definitively eliminate localized gingiva enlargements and to simultaneously correct consecutive Miller class I II-III. recessions, esthetic disturbances. (Ethical committee permission number: SE RKEB: 185\u002F2020.)",[522,523,25,524],"Localized Gingival Enlargement","Epulides","Periodontal; Lesion",[526,527,528,522],"Periodontal reconstructive surgery","Surgical excision","Surgical treatment","2025-04-01",{"date":531,"type":31},"2025-04-04",{"date":533,"type":31},"2024-01-05",{"date":535,"type":20},"2025-12",{"name":537,"class":38},"Semmelweis University",{"id":539,"slug":4,"hasResults":11,"nctId":540,"briefTitle":541,"officialTitle":542,"acronym":543,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":545,"targetDuration":4,"studyType":49,"phases":546,"briefSummary":547,"conditions":548,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":551,"lastUpdatePostDateStruct":552,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":73},"100571836","NCT06725433","Nissen Versus Dor Hiatal Hernia Repair","NiDor-study: a Randomized Controlled Trial Comparing Nissen and Dor Fundoplication in Hiatal Hernia Repair","NiDor","Inclusion Criteria:\n\n* At least 18 years of age\n* Type II-IV hiatal hernia, confirmed by radiology or endoscopy\n* Scheduled for mini-invasive hiatal hernia repair\n* Emergency mini-invasive surgery for hiatal hernia\n* The informed consent is acquired\n\nExclusion Criteria:\n\n* Recurrent hiatal hernia\n* Need for esophageal lengthening procedure (Collis)\n* Gangrene or need for any resection during (emergency) surgery\n* Need for laparotomy or thoracotomy\u002Fthoracoscopy\n* No written consent",{"count":19,"type":20},[51],"Hiatal hernia can present with a wide range of symptoms. An usual surgical repair technique usually includes Nissen fundoplication, while other procedures are less frequently employed. However, recurrence and reoperation rates remain high. This randomized controlled trial aims to compare the efficacy of Nissen and Dor fundoplication in preventing hiatal hernia recurrence and reducing the risk of reoperation\n\nParticipants undergoing minimally invasive hiatal hernia repair will be randomly assigned to either Nissen or Dor fundoplication. Postoperatively at 12 months, anatomical recurrence rates based on computed tomography scans and symptomatic recurrence rates, anti-reflux medication use, GERD-related quality of life, and dysphagia symptoms will be assessed. A subsequent long-term follow-up study will conducted afterwards utilizing national registry data to evaluate reoperation rates and anti-reflux medication use",[549,550,25],"Hiatal Hernia","Paraesophageal Hernia","2025-02-17",{"date":553,"type":31},"2025-02-19",{"date":555,"type":31},"2025-02-07",{"date":557,"type":20},"2030-01-30",{"name":559,"class":38},"Kuopio University Hospital",{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":4,"eligibilityCriteria":565,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":4,"enrollmentInfo":566,"targetDuration":81,"studyType":21,"phases":4,"briefSummary":568,"conditions":569,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":73},"100557757","NCT06542263","Clinical Study on the Effect of CPAP on AF Recurrence After Catheter Ablation in Patients with AF and OSA","Clinical Study on the Effect of Continuous Positive Airway Pressure Ventilation on Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Atrial Fibrillation and Obstructive Sleep Apnea","Inclusion Criteria:\n\n1. Clinical diagnosis of AF combined with moderate to severe OSA (OSA diagnostic criteria: apnea hypopnea index (AHI) greater than 15\u002Fhour, and at least 80% of all events are respiratory sleep obstructive events; AF includes persistent atrial fibrillation and paroxysmal atrial fibrillation)\n2. Age ≥ 18 years old\n3. The patient voluntarily participates in the project and signs informed consent\n4. All patients undergo overnight sleep pressure titration at the sleep center to determine the minimum pressure value for continuous positive airway pressure ventilation at home. All patients are required to undergo CPAP treatment at home at least 5 days a week, with each session lasting at least 4 hours\n\nExclusion Criteria:\n\n1. Patients with neuromuscular disorders, pulmonary hypopnea, and severe lung diseases\n2. Preoperative confirmation of thrombus in the left atrium\n3. The patient has no desire for conversion\n4. Secondary atrial fibrillation (hyperthyroidism, tumors, etc.)\n5. Individuals with contraindications to anticoagulants\n6. Left atrial diameter (LAD) exceeding 60mm (2D echocardiography long axis section data)\n7. Pregnant women\n8. History of myocardial infarction, percutaneous coronary intervention, and cardiac surgery in the past three months\n9. Stroke or transient ischemic attack in the past six months\n10. After artificial valve implantation surgery\n11. Severe renal insufficiency (creatinine Cr\\>2.5mg\u002Fdl or\\>221umol\u002FL, or glomerular filtration rate eGFR\\\u003C30ml\u002Fmin\u002F1.73m2)\n12. Acute diseases or active infections that occur before surgery, recorded as pain, fever, positive blood culture, and\u002For leukocytosis, or have been treated with antibiotics.\n13. Expected survival period\\\u003C1 year",{"count":567,"type":20},224,"Atrial fibrillation (AF) is the most common sustained arrhythmia in clinical practice, significantly increasing the risks of death, stroke, heart failure, cognitive impairment, and dementia, thus severely impacting patients' quality of life. However, for AF patients with concomitant cardiovascular risk factors, particularly those with obstructive sleep apnea (OSA), the success rate of catheter ablation is significantly reduced. Continuous positive airway pressure (CPAP) is currently an effective treatment for OSA, effectively correcting nocturnal intermittent hypoxia and fragmented sleep caused by OSA. However, the effect of CPAP therapy on AF recurrence in patients with OSA undergoing catheter ablation remains controversial. Faced with conflicting research findings, our team recently conducted a meta-analysis (registration number CRD42023398588) to assess the impact of CPAP on AF recurrence post catheter ablation in patients with AF and OSA, suggesting that CPAP significantly reduces AF recurrence post catheter ablation (RR = 0.58, P \\\u003C 0.01). However, considering the limited number of included studies, potential bias risks, and confounding factors, our meta-analysis results await further confirmation through real-world studies by our team. Therefore, our team plans to conduct further research on the impact of CPAP on AF recurrence post catheter ablation in patients with moderate to severe OSA, aiming to provide clinical guidance for the treatment of AF in patients with moderate to severe OSA.",[570,571,572,25,573],"Atrial Fibrillation","Continuous Positive Airway Pressure","Obstructive Sleep Apnea","Observational Study","2025-01-20",{"date":576,"type":31},"2025-01-23",{"date":578,"type":31},"2024-08-09",{"date":580,"type":20},"2026-08-01",{"name":582,"class":38},"Second Affiliated Hospital of Soochow University",{"id":584,"slug":4,"hasResults":11,"nctId":585,"briefTitle":586,"officialTitle":587,"acronym":4,"eligibilityCriteria":588,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":589,"enrollmentInfo":590,"targetDuration":4,"studyType":49,"phases":592,"briefSummary":593,"conditions":594,"keywords":4,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":602,"lastUpdatePostDateStruct":603,"startDateStruct":605,"completionDateStruct":607,"leadSponsor":609,"locationsCount":4},"100576924","NCT06791616","Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm","Evaluation of Surveillance Intervals After Piecemeal Resection of Non-pedunculated Colorectal Lesions ≥20mm: SCARFACE Clinical Trial","Inclusion Criteria:\n\n* Patients with a single non-pedunculated colorectal lesion (NPCL) ≥20 mm that has been resected piecemeal and treated with thermal ablation (using snare tip or argon plasma) at the margins as prophylaxis against recurrence, and who are awaiting the initiation of specific endoscopic follow-up.\n* Complete colonoscopy with adequate or excellent bowel preparation performed within the last 6 months prior to the resection of the index lesion.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Resection performed using a cold snare technique due to the high risk of recurrence.\n* Histology of the lesion showing malignancy: colorectal cancer with submucosal invasion, regardless of invasion depth in microns.\n* Absence of information regarding the grade of dysplasia of the index lesion.\n* Personal history of colorectal cancer.\n* Incomplete endoscopic resection of the index lesion or any other polyps present in the patient.\n* When the endoscopist performing the index colonoscopy expresses doubts about whether the resection was complete.\n* Index lesion with prior attempted resection.\n* Hereditary cancer syndromes (e.g., adenomatous or serrated polyposis syndromes, Lynch syndrome, etc.).\n* Inflammatory bowel disease.\n* Severe comorbidities with reduced life expectancy.\n* Pregnancy.\n* Ongoing cytotoxic treatment or radiotherapy for a malignant disease.","85 Years",{"count":591,"type":20},746,[51],"Intensive endoscopic surveillance following piecemeal resection of non-pedunculated colorectal lesions (NPCL) ≥20 mm is the current standard of care, given the high recurrence rate of these lesions (15-30%). However, most recurrences are detected at 12 months, are small and unifocal, and can be easily resected endoscopically. Furthermore, thermal margin ablation has demonstrated a reduction in recurrence rates to 5-6%, highlighting the need to optimize current surveillance protocols, which are costly, invasive, and impose a significant clinical burden.\n\nThe multicenter SCARFACE clinical trial aims to evaluate whether a reduced surveillance protocol (at 12 and 48 months) is non-inferior to the standard protocol (at 6, 12, and 48 months) in terms of recurrence rates, using a predefined non-inferiority margin. This non-inferiority design aims to determine if the reduced protocol maintains acceptable efficacy while reducing clinical workload and minimizing risks and discomfort associated with intensive follow-up.\n\nPatients will be randomized in a 1:1 ratio into the two surveillance protocols, with an estimated sample size of 746 lesions. The primary objective is to compare the cumulative incidence of recurrence at 12 months. Secondary objectives include characterizing recurrences, assessing complications associated with endoscopic treatments and evaluating the incidence of advanced colorectal lesions. The findings of this study are expected to directly impact clinical guidelines and routine practice, optimizing resource utilization and improving patient quality of life.",[595,596,597,598,599,600,601,25],"Colorectal Neoplasms","Adenoma Colon","Colonic Polyps","Serrated Adenoma","Endoscopic Mucosal Resection","Non-pedunculated Lesions","Thermal Ablation","2025-01-19",{"date":604,"type":31},"2025-01-24",{"date":606,"type":20},"2025-03-01",{"date":608,"type":20},"2030-05-31",{"name":610,"class":38},"Asociación Española de Gastroenterología",{"id":612,"slug":4,"hasResults":11,"nctId":613,"briefTitle":614,"officialTitle":615,"acronym":4,"eligibilityCriteria":616,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":319,"enrollmentInfo":617,"targetDuration":4,"studyType":49,"phases":619,"briefSummary":621,"conditions":622,"keywords":625,"overallStatus":231,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":4},"100571378","NCT06719479","A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R\u002FM HNSCC or NPC(Note: It is Currently Phase II.).","A Phase II\u002FIII Clinical Trial to Evaluate the Effect of IAE0972 Combined with Chemotherapy Selected by Doctors for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\u002FNasopharyngeal Carcinoma.","Inclusion Criteria:\n\n1. The age is 18\\~75 years old (including the critical value), regardless of gender.\n2. Phase II cohort 1, cohort 2: locally advanced squamous cell carcinoma of the head and neck which only occurred in the oral cavity, oropharynx, hypopharynx and larynx after histological diagnosis or had no indication of radical local treatment; In the past, I only received ≤2 line therapy for recurrent and metastatic head and neck squamous cell carcinoma.\n3. Phase II cohort 3, cohort 4, cohort 5: Histologically confirmed nasopharyngeal carcinoma, stage IVb or recurrent nasopharyngeal carcinoma that is not suitable for local treatment according to the TNM of AJCC nasopharyngeal carcinoma in the 8th edition of 2017; In the past, they only received ≤2 line therapy for recurrent and metastatic nasopharyngeal carcinoma.\n4. According to the researcher's judgment, the chemotherapy in this experiment is applicable.\n5. According to the RECIST 1.1 standard, there is at least one measurable lesion (tumor lesions located in previous radiotherapy areas or other local regional treatment sites are generally not regarded as measurable lesions, unless the lesions make clear progress or persist after radiotherapy for three months).\n6. The score of physical condition of the ECOG is 0\\~1.\n7. The estimated survival time is ≥3 months.\n8. Have sufficient organ functions:\n\n   * Blood system (no blood transfusion or hematopoietic stimulating factor treatment within 14 days): ANC≥1.5×109\u002FL, PLT≥90×109\u002FL, HGB≥ 90 g\u002FL; ② Liver function: TBIL≤1.5 times the ULN, except Gilbert syndrome; AST and ALT are ≤3.0 times ULN, while subjects with liver metastasis or liver cancer need AST and ALT≤3.0 times ULN and total bilirubin ≤ 3.0 times ULN;\n\n     * Renal function: Cr≤1.5 times ULN; If the creatinine is more than 1.5 times ULN, the CCR should be ≥ 50 ml\u002Fmin (calculated according to Cockcroft-Gault formula);\n\n       * Coagulation function: INR≤1.5 times ULN, APTT≤1.5 times ULN, and INR and APTT≤2.5 times ULN for patients with liver metastasis or liver cancer.\n9. Qualified fertile subjects (male and female) must agree to use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners during the trial and at least 6 months after the last medication; The blood pregnancy test of female subjects of childbearing age must be negative within 7 days before the first use of the study drug.\n10. Subjects must give informed consent to this study before the experiment, and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Having received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks before the first use of the investigating drug, the following drugs should be excluded according to the following criteria:\n\n   ① Nitrosourea or mitomycin C was used within 6 weeks before the first use of the study drug;\n\n   ② Oral administration of fluorouracil and small molecule targeted drugs 2 weeks before the first use of the study drug or within 5 half-lives of the drug (whichever is longer);\n\n   ③ Chinese patent drugs with anti-tumor indications were used within 2 weeks before the first use of the study drugs.\n2. Received other unlisted clinical research drugs or treatments within 4 weeks before using the research drugs.\n3. The adverse reactions of previous anti-tumor treatments have not recovered to NCI CTCAE 5.0 grade evaluation ≤1 grade or the relevant provisions of the selection criteria (except for the toxicity that the researchers judged to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.).\n4. It is known that it has hypersensitivity to any antibody drugs (NCI CTCAE 5.0 rating is ≥3), or it has hypersensitivity to research drugs, active ingredients or inactive excipients of chemotherapy schemes.\n5. Have received major surgery (excluding puncture biopsy), major trauma or need to undergo elective surgery during the trial within 4 weeks before the first use of the study drug.\n6. Having received systemic corticosteroids (prednisone \\> 10 mg\u002Fday or similar drugs with the same dose) within 14 days before the first use of the study drug, except for the following cases: using topical, ophthalmic, intra-articular and intranasal corticosteroids; Short-term use of glucocorticoids for preventive treatment (for example, prevention of contrast agent allergy).\n7. Treatment with other immunosuppressants within 28 days or 5 half-lives (whichever is longer) before the first use of the study drug.\n8. Have used immunomodulatory drugs within 14 days before the first use of the study drug (Appendix 5).\n9. Have been vaccinated with any live vaccine within 4 weeks before the first use of the study drug.\n10. Received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past.\n11. Brain parenchymal metastasis or meningeal metastasis with clinical symptoms.\n12. It has active infection and needs intravenous anti-infection treatment at present.\n13. Have a history of immunodeficiency disease, including positive detection of HIV antibody.\n14. Active hepatitis B (HBsAg positive and HBV-DNA positive or above the upper limit of normal value) and active hepatitis C (HCV antibody positive and HCV RNA positive or above the upper limit of normal value).\n15. Having serious and uncontrollable lung diseases (severe infectious pneumonia, interstitial lung disease, etc.).\n16. Have a serious history of cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    ① Severe cardiac rhythm or conduction abnormality, such as ventricular arrhythmia requiring clinical intervention and II-III degree atrioventricular block;\n\n    ② The mean QT interval (QTcF) corrected by Fridericia method was≥470 ms；\n\n    ③ Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months before the first administration; (4) There is heart failure or LVEF less than 50% with the NYHA cardiac function classification ≥II or structural heart disease with high risk judged by other researchers;\n\n    ⑤ Clinically uncontrollable hypertension.\n17. Suffering from active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), with the exception of clinically stable autoimmune thyroiditis, type I diabetes, vitiligo, cured atopic dermatitis in children, psoriasis that does not require systemic treatment (within the past 2 years), etc.\n18. Suffering from other malignant tumors within 5 years before the start of study administration, except for the following cases: malignant tumors that can be expected to be cured after treatment (including but not limited to thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer or breast ductal carcinoma in situ treated by radical surgery).\n19. There is clinically uncontrollable effusion in the third space, which is judged by the researcher to be unsuitable for the group.\n20. Known alcohol or drug dependence.\n21. Have mental disorder or poor compliance.\n22. Pregnant or lactating women.\n23. The researcher thinks that the subject has other serious history of systemic diseases, or is not suitable to participate in this clinical study for other reasons.",{"count":618,"type":20},60,[86,620],"PHASE3","Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R\u002FM HNSCC\u002FNPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.\n\nPhase III: According to the RECIST 1.1, the effectiveness of IAE0972 combined with chemotherapy regimen chosen by doctors compared with placebo plus chemotherapy regimen chosen by doctors was evaluated through OS in patients with R\u002FM NPC who failed or progressed after treatment with ≤2-line system.",[623,624,25,456],"NPC","HNSCC",[623,624,25,456],"2024-12-02",{"date":628,"type":31},"2024-12-05",{"date":630,"type":20},"2025-01-01",{"date":632,"type":20},"2028-01-01",{"name":634,"class":140},"SUNHO（China）BioPharmaceutical CO., Ltd.",""]